NCT00044720View on ClinicalTrials.gov

Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients

PHASE4CompletedINTERVENTIONAL
Enrollment

484

Participants

Timeline

Start Date

Not specified

Primary Completion Date

July 31, 2005

Study Completion Date

July 31, 2005

Conditions
Chronic Kidney FailureGraft vs Host DiseaseKidney Transplantation
Interventions
DRUG

Rapamune

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00044720 - Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients | Biotech Hunter | Biotech Hunter